The Experts below are selected from a list of 243 Experts worldwide ranked by ideXlab platform
Antoni Ribas - One of the best experts on this subject based on the ideXlab platform.
-
squamous cell carcinoma arising in long standing Necrobiosis Lipoidica
Journal of The European Academy of Dermatology and Venereology, 2004Co-Authors: Jorge Santosjuanes, Cristina Galache, J R Curto, M P Carrasco, Antoni RibasAbstract:: Necrobiosis Lipoidica (NL) is a disease of collagen. Squamous cell carcinomas developing in areas of chronic ulceration and scarring have been well documented in a variety of skin diseases but rarely in areas of Necrobiosis Lipoidica. The case history of a 76-year-old female is presented, whose squamous cell carcinoma appeared 30 years after the diagnosis of Necrobiosis Lipoidica. The clinical and histopathological picture is described, stressing the importance of the unusual association of the two pathologies in the prognostic.
A A Khaleeli - One of the best experts on this subject based on the ideXlab platform.
-
squamous cell carcinoma developing in Necrobiosis Lipoidica
Diabetic Medicine, 2001Co-Authors: K E Imtiaz, A A KhaleeliAbstract:We describe a case of squamous cell carcinoma arising in long-standing Necrobiosis Lipoidica in a type 1 female diabetic patient. The tumour and the skin lesion were successfully excised and repaired with full thickness skin graft. The development of squamous cell carcinoma in association with this skin disorder is rare (only four cases reported in literature since 1966), but should be considered in chronic, non-healing and recalcitrant ulcers developing within areas of Necrobiosis Lipoidica.
Jorge Santosjuanes - One of the best experts on this subject based on the ideXlab platform.
-
squamous cell carcinoma arising in long standing Necrobiosis Lipoidica
Journal of The European Academy of Dermatology and Venereology, 2004Co-Authors: Jorge Santosjuanes, Cristina Galache, J R Curto, M P Carrasco, Antoni RibasAbstract:: Necrobiosis Lipoidica (NL) is a disease of collagen. Squamous cell carcinomas developing in areas of chronic ulceration and scarring have been well documented in a variety of skin diseases but rarely in areas of Necrobiosis Lipoidica. The case history of a 76-year-old female is presented, whose squamous cell carcinoma appeared 30 years after the diagnosis of Necrobiosis Lipoidica. The clinical and histopathological picture is described, stressing the importance of the unusual association of the two pathologies in the prognostic.
K E Imtiaz - One of the best experts on this subject based on the ideXlab platform.
-
squamous cell carcinoma developing in Necrobiosis Lipoidica
Diabetic Medicine, 2001Co-Authors: K E Imtiaz, A A KhaleeliAbstract:We describe a case of squamous cell carcinoma arising in long-standing Necrobiosis Lipoidica in a type 1 female diabetic patient. The tumour and the skin lesion were successfully excised and repaired with full thickness skin graft. The development of squamous cell carcinoma in association with this skin disorder is rare (only four cases reported in literature since 1966), but should be considered in chronic, non-healing and recalcitrant ulcers developing within areas of Necrobiosis Lipoidica.
Gottfried Tappeiner - One of the best experts on this subject based on the ideXlab platform.
-
Necrobiosis Lipoidica treatment with systemic corticosteroids
British Journal of Dermatology, 2008Co-Authors: Peter Petzelbauer, Klaus Wolff, Gottfried TappeinerAbstract:Summary In an attempt to find an effective therapy for Necrobiosis Lipoidica, we have treated six patients with this disease with a 5-week course of systemic corticosteroids. This treatment resulted in complete cessation of disease activity in all patients and no recurrence in a mean follow-up period of 7 months; however, restitution of atrophic skin lesions could not be achieved. The therapy was well tolerated and did not pose problems, even in diabetic patients. These results strongly suggest that short-course therapy of Necrobiosis Lipoidica with corticosteroids is of lasting benefit to these patients and should probably be considered early in the course of their skin disease.
